X

Trial Profile

A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofatumumab (Primary) ; Chlorambucil
Indications Chronic lymphocytic leukaemia
Focus Registrational; Therapeutic Use
Acronyms COMPLEMENT 1
Sponsors Genmab; GlaxoSmithKline; GSK; Novartis; Novartis Pharmaceuticals

Most Recent Events

27 Jul 2020 This trial has been completed in United Kingdom as per European Clinical Trials Database reocrd (global end of the trial 2016-05-06)
05 Jun 2019 Status changed from completed to discontinued.
04 Jun 2019 Results (n=447) presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO 2019).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com